Xenon Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 182.39 million compared to USD 125.37 million a year ago. Basic loss per share from continuing operations was USD 2.73 compared to USD 2.06 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.45 USD | -0.32% | -5.78% | -12.18% |
05-10 | Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating | MT |
05-09 | Xenon Pharmaceuticals Q1 Net Loss Narrows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.18% | 3.06B | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023